Roles and mechanisms of alternative splicing in cancer—implications for care

SC Bonnal, I López-Oreja, J Valcárcel - Nature reviews Clinical …, 2020 - nature.com
Removal of introns from messenger RNA precursors (pre-mRNA splicing) is an essential
step for the expression of most eukaryotic genes. Alternative splicing enables the regulated …

A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target

A Ghelli Luserna di Rorà, C Cerchione… - Journal of Hematology & …, 2020 - Springer
The inhibition of the DNA damage response (DDR) pathway in the treatment of cancer has
recently gained interest, and different DDR inhibitors have been developed. Among them …

Streamlined single-cell proteomics by an integrated microfluidic chip and data-independent acquisition mass spectrometry

ST Gebreyesus, AA Siyal, RB Kitata, ESW Chen… - Nature …, 2022 - nature.com
Single-cell proteomics can reveal cellular phenotypic heterogeneity and cell-specific
functional networks underlying biological processes. Here, we present a streamlined …

Targeting Wee1 kinase as a therapeutic approach in Hematological Malignancies

S Vakili-Samiani, AT Jalil, WK Abdelbasset… - DNA repair, 2021 - Elsevier
Hematologic malignancies include various diseases that develop from hematopoietic stem
cells of bone marrow or lymphatic organs. Currently, conventional DNA-damage-based …

Targeting mRNA processing as an anticancer strategy

J Desterro, P Bak-Gordon… - Nature Reviews Drug …, 2020 - nature.com
Discoveries in the past decade have highlighted the potential of mRNA as a therapeutic
target for cancer. Specifically, RNA sequencing revealed that, in addition to gene mutations …

A SIRT7-dependent acetylation switch regulates early B cell differentiation and lineage commitment through Pax5

A Gamez-Garcia, M Espinosa-Alcantud… - Nature …, 2024 - nature.com
B lymphopoiesis is orchestrated by lineage-specific transcription factors. In B cell
progenitors, lineage commitment is mediated by Pax5, which is commonly mutated in B cell …

Proteogenomics refines the molecular classification of chronic lymphocytic leukemia

SA Herbst, M Vesterlund, AJ Helmboldt, R Jafari… - Nature …, 2022 - nature.com
Cancer heterogeneity at the proteome level may explain differences in therapy response
and prognosis beyond the currently established genomic and transcriptomic-based …

In silico investigations identified Butyl Xanalterate to competently target CK2α (CSNK2A1) for therapy of chronic lymphocytic leukemia

SA Alsagaby, D Iqbal, I Ahmad, H Patel, SA Mir… - Scientific reports, 2022 - nature.com
Chronic lymphocytic leukemia (CLL) is an incurable malignancy of B-cells. In this study,
bioinformatics analyses were conducted to identify possible pathogenic roles of CK2α …

RNA-binding proteins in hematopoiesis and hematological malignancy

DJ Hodson, M Screen, M Turner - Blood, The Journal of the …, 2019 - ashpublications.org
RNA-binding proteins (RBPs) regulate fundamental processes, such as differentiation and
self-renewal, by enabling the dynamic control of protein abundance or isoforms or through …

The protein landscape of chronic lymphocytic leukemia

F Meier-Abt, J Lu, E Cannizzaro… - Blood, The Journal …, 2021 - ashpublications.org
Many functional consequences of mutations on tumor phenotypes in chronic lymphocytic
leukemia (CLL) are unknown. This may be in part due to a scarcity of information on the …